Amylyx Pharmaceuticals Canada has entered into product listing agreements with Quebec and Ontario to publicly reimburse Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), which was recently approved for amyotrophic lateral sclerosis (ALS). The oral therapy, which is marketed in the U.S. as Relyvrio, has been added to the…

NurOwn, an experimental treatment, significantly lowered neurofilament light chain (NfL) levels in the spinal fluid, a marker of nerve damage, and this seems to predict slower disease progression in amyotrophic lateral sclerosis (ALS) patients. That’s according to a new analysis of Phase 3 clinical trial (NCT03280056) data…

A grant given to a researcher at the University of Albany in New York will support further work into specific RNA molecules, called RNA aptamers, that have shown early promise in treating amyotrophic lateral sclerosis (ALS). The $768,825 U.S. Department of Defense award to Li Niu, PhD, a chemistry…

CNM-Au8 extended long-term survival and slowed disease progression in adults with early stage amyotrophic lateral sclerosis (ALS) compared with a placebo, according to final data from the RESCUE-ALS clinical trial and one-year findings in its open-label extension (OLE). Patients treated initially with CNM-Au8 in the main trial experienced…

The technology company Unlearn has joined with QurAlis to use artificial intelligence (AI) to speed up clinincal trials for amyotrophic lateral sclerosis (ALS). The aim of the collaboration is to minimize variability and increase the statistical strength of QurAlis’ clinical trials that are evaluating their primary ALS…

Arrowhead Pharmaceuticals has filed an application in Australia seeking the green light to launch the first clinical trial of ARO-SOD1, its RNA-based therapy for amyotrophic lateral sclerosis (ALS). The therapy is designed to reduce SOD1 protein levels in ALS patients carrying SOD1 mutations, which are estimated to account…

High blood levels of an omega-3 fatty acid is associated with a significantly slower disease progression and longer life among people with amyotrophic lateral sclerosis (ALS), a study reported. The link specifically was seen in people with elevated blood levels of an omega-3 fatty acid called alpha-linolenic acid…

A new genetic risk score that takes hundreds of different genetic variations into account may help predict who’s most likely to develop amyotrophic lateral sclerosis (ALS). The score needs to be validated in future studies before being used in the clinic, but could be important to stratify people according…

The French medtech company BrainTale has raised €4.5 million (about $4.9 million) to support the development of a noninvasive imaging analysis platform to help diagnose and monitor amyotrophic lateral sclerosis (ALS) and other neurological disorders. The platform, called BrainTale-care, is a digital medical platform that examines MRI scans…

Work into developing molecules that block microRNA-155 (miR-155) as potential treatments for amyotrophic lateral sclerosis (ALS) has advanced to the stage of testing candidate molecules in animal models of the disease. Initiated last year, the miR-155 project is a collaboration between scientists at Regulus Therapeutics and Brigham…